Erratum: P53 expression in patients with advanced urothelial cancer of the urinary bladder (BJU International (2010) 105: (489-95) DOI: 10.1111/j.1464-410X.2009.08742.x);P53 expression in patients with advanced urothelial cancer of the urinary bladder

BJU International

Volumn 105, Issue 4, 2010, Pages 489-495

  Shariat, Shahrokh F ^a   Bolenz, Christian ^a   Karakiewicz, Pierre I ^b   Fradet, Yves ^c   Ashfaq, Raheela ^a   Bastian, Patrick J ^d,e   Nielsen, Matthew E ^f   Capitanio, Umberto ^b,g   Jeldres, Claudio ^b,g   Rigaud, Jérôme ^c   Müller, Stefan C ^d   Lerner, Seth P ^h   Montorsi, Francesco ^g   Sagalowsky, Arthur I ^a   Cote, Richard J ⁱ   Lotan, Yair ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c LAVAL UNIVERSITY   (Canada)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e UNIVERSITY OF BONN   (Germany)

^f JOHNS HOPKINS HOSPITAL   (United States)

^g VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^h BAYLOR COLLEGE OF MEDICINE   (United States)

ⁱ UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Bladder cancer; Immunohistochemistry; Lymph node metastasis; P53; Recurrence; Survival

Indexed keywords

PROTEIN P53;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLADDER CARCINOMA; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE; SURVIVAL TIME;

EID: 76149145040     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.13166     Document Type: Erratum

References (33)

1. Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol 2007 8 : 275 283
2. Malats N, Bustos A, Nascimento CM et al. P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol 2005 6 : 678 686
3. Esrig D, Elmajian D, Groshen S et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994 331 : 1259 1264
4. Stein JP, Grossfeld GD, Ginsberg DA et al. Prognostic markers in bladder cancer: a contemporary review of the literature. J Urol 1998 160 : 645 659
5. Schmitz-Drager BJ, Goebell PJ, Ebert T, Fradet Y. p53 immunohistochemistry as a prognostic marker in bladder cancer. Playground for urology scientists? Eur Urol 2000 38 : 691 699
6. Shariat SF, Zlotta AR, Ashfaq R, Sagalowsky AI, Lotan Y. Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness. Mod Pathol 2007 20 : 445 459
7. Shariat SF, Tokunaga H, Zhou J et al. p53, 21 pRB and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol 2004 22 : 1014 1024
8. Frank I, Cheville JC, Blute ML et al. Prognostic value of p53 and MIB-1 in transitional cell carcinoma of the urinary bladder with regional lymph node involvement. Cancer 2004 101 : 1803 1808
9. Tzai TS, Tsai YS, Chow NH. The prevalence and clinicopathologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer. Urol Oncol 2004 22 : 112 118
10. Fleshner N, Kapusta L, Ezer D, Herschorn S, Klotz L. p53 nuclear accumulation is not associated with decreased disease-free survival in patients with node positive transitional cell carcinoma of the bladder. J Urol 2000 164 : 1177 1182
11. Shariat SF, Karakiewicz PI, Palapattu GS et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol 2006 176 : 2414 2422
12. Shariat SF, Palapattu GS, Karakiewicz PI et al. Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. Eur Urol 2007 51 : 137 151
13. Chatterjee SJ, Datar R, Youssefzadeh D et al. Combined effects of p53, 21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol 2004 22 : 1007 1013
14. Stein JP, Lieskovsky G, Cote R et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001 19 : 666 675
15. Cote RJ, Dunn MD, Chatterjee SJ et al. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res 1998 58 : 1090 1094
16. Sarkis AS, Dalbagni G, Cordon-Cardo C et al. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst 1993 85 : 53 9
17. Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y. Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis. Hum Pathol 2006 37 : 1568 1576
18. Cote RJ, Esrig D, Groshen S, Jones PA, Skinner DG. p53 and treatment of bladder cancer. Nature 1997 385 : 123 125
19. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994 81 : 515 519
20. Fine JP. Regression modeling of competing crude failure probabilities. Biostatistics 2001 2 : 85 97
21. Harrell FE Jr, Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating the yield of medical tests. JAMA 1982 247 : 2543 2546
22. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Statistics Med 1996 15 : 361 387
23. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000 408 : 307 310
24. Serth J, Kuczyk MA, Bokemeyer C et al. p53 immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder. Br J Cancer 1995 71 : 201 205
25. George B, Datar RH, Wu L et al. p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer. J Clin Oncol 2007 25 : 5352 5358
26. Kattan MW. Judging new markers by their ability to improve predictive accuracy. J Natl Cancer Inst 2003 95 : 634 635
27. Shariat SF, Karakiewicz PI, Ashfaq R et al. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer 2008 112 : 315 325
28. Vickers AJ, Jang K, Sargent D, Lilja H, Kattan MW. Systematic review of statistical methods used in molecular marker studies in cancer. Cancer 2008 112 : 1862 1868
29. Sjogren S, Inganas M, Norberg T et al. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst 1996 88 : 173 182
30. Abdel-Fattah R, Challen C, Griffiths TR, Robinson MC, Neal DE, Lunec J. Alterations of TP53 in microdissected transitional cell carcinoma of the human urinary bladder: high frequency of TP53 accumulation in the absence of detected mutations is associated with poor prognosis. Br J Cancer 1998 77 : 2230 2238
31. Qureshi KN, Griffiths TR, Robinson MC et al. TP53 accumulation predicts improved survival in patients resistant to systemic cisplatin-based chemotherapy for muscle-invasive bladder cancer. Clin Cancer Res 1999 5 : 3500 3507
32. Watanabe J, Nishiyama H, Okubo K et al. Clinical evaluation of p53 mutations in urothelial carcinoma by IHC and FASAY. Urology 2004 63 : 989 993
33. Madersbacher S, Hochreiter W, Burkhard F et al. Radical cystectomy for bladder cancer today - a homogeneous series without neoadjuvant therapy. J Clin Oncol 2003 21 : 690 696